Comparative Pharmacology
Head-to-head clinical analysis: KADCYLA versus VYLOY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADCYLA versus VYLOY.
KADCYLA vs VYLOY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
VYLOY (zolbetuximab-clzb) is a chimeric IgG1 monoclonal antibody that binds to claudin 18.2 (CLDN18.2), a tight junction protein expressed on the surface of gastric cancer cells. Binding induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to tumor cell death.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
VYLOY (zolbetuximab-clzb) is administered intravenously at a dose of 800 mg every 2 weeks following a loading dose of 1200 mg on day 1 of cycle 1.
None Documented
None Documented
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Approximately 2.2 hours (terminal elimination half-life); clinical context: supports twice-weekly dosing schedule.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent